Resistance to therapy caused by intragenic deletion in BRCA2 SL Edwards, R Brough, CJ Lord, R Natrajan, R Vatcheva, DA Levine, ... Nature 451 (7182), 1111-1115, 2008 | 1127 | 2008 |
Complex landscapes of somatic rearrangement in human breast cancer genomes PJ Stephens, DJ McBride, ML Lin, I Varela, ED Pleasance, JT Simpson, ... Nature 462 (7276), 1005-1010, 2009 | 1026 | 2009 |
BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells G Molyneux, FC Geyer, FA Magnay, A McCarthy, H Kendrick, R Natrajan, ... Cell stem cell 7 (3), 403-417, 2010 | 927 | 2010 |
FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer N Turner, A Pearson, R Sharpe, M Lambros, F Geyer, MA Lopez-Garcia, ... Cancer research 70 (5), 2085-2094, 2010 | 837 | 2010 |
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer SA Eccles, EO Aboagye, S Ali, AS Anderson, J Armes, F Berditchevski, ... Breast Cancer Research 15, 1-37, 2013 | 524 | 2013 |
Breast cancer molecular profiling with single sample predictors: a retrospective analysis B Weigelt, A Mackay, R A'hern, R Natrajan, DSP Tan, M Dowsett, ... The lancet oncology 11 (4), 339-349, 2010 | 490 | 2010 |
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets N Turner, MB Lambros, HM Horlings, A Pearson, R Sharpe, R Natrajan, ... Oncogene 29 (14), 2013-2023, 2010 | 473 | 2010 |
β-Catenin pathway activation in breast cancer is associated with triple-negative phenotype but not with CTNNB1 mutation FC Geyer, M Lacroix-Triki, K Savage, M Arnedos, MB Lambros, A MacKay, ... Modern pathology 24 (2), 209-231, 2011 | 432 | 2011 |
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors KJ Dedes, D Wetterskog, AM Mendes-Pereira, R Natrajan, MB Lambros, ... Science translational medicine 2 (53), 53ra75-53ra75, 2010 | 410 | 2010 |
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer DR Robinson, S Kalyana-Sundaram, YM Wu, S Shankar, X Cao, B Ateeq, ... Nature medicine 17 (12), 1646-1651, 2011 | 406 | 2011 |
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity I Bajrami, JR Frankum, A Konde, RE Miller, FL Rehman, R Brough, ... Cancer research 74 (1), 287-297, 2014 | 386 | 2014 |
Identification of a disease-defining gene fusion in epithelioid hemangioendothelioma MR Tanas, A Sboner, AM Oliveira, MR Erickson-Johnson, J Hespelt, ... Science translational medicine 3 (98), 98ra82-98ra82, 2011 | 384 | 2011 |
Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C NH Dryden, LR Broome, F Dudbridge, N Johnson, N Orr, S Schoenfelder, ... Genome research 24 (11), 1854-1868, 2014 | 287 | 2014 |
SF3B1 mutations constitute a novel therapeutic target in breast cancer SL Maguire, A Leonidou, P Wai, C Marchiò, CKY Ng, A Sapino, ... The Journal of pathology 235 (4), 571-580, 2015 | 256 | 2015 |
Molecular analysis reveals a genetic basis for the phenotypic diversity of metaplastic breast carcinomas FC Geyer, B Weigelt, R Natrajan, MBK Lambros, D de Biase, R Vatcheva, ... The Journal of Pathology: A Journal of the Pathological Society of Great …, 2010 | 245 | 2010 |
Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes M Clarke, A Mackay, B Ismer, JC Pickles, RG Tatevossian, S Newman, ... Cancer discovery 10 (7), 942-963, 2020 | 238 | 2020 |
Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors TA Yap, B O’Carrigan, MS Penney, JS Lim, JS Brown, ... Journal of Clinical Oncology 38 (27), 3195-3204, 2020 | 209 | 2020 |
Mucinous carcinoma of the breast is genomically distinct from invasive ductal carcinomas of no special type M Lacroix‐Triki, PH Suarez, A MacKay, MB Lambros, R Natrajan, ... The Journal of pathology 222 (3), 282-298, 2010 | 205 | 2010 |
Genomic and mutational profiling of ductal carcinomas in situ and matched adjacent invasive breast cancers reveals intra‐tumour genetic heterogeneity and clonal … L Hernandez, PM Wilkerson, MB Lambros, A Campion‐Flora, ... The Journal of pathology 227 (1), 42-52, 2012 | 198 | 2012 |
FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo R Sharpe, A Pearson, MT Herrera-Abreu, D Johnson, A Mackay, JC Welti, ... Clinical Cancer Research 17 (16), 5275-5286, 2011 | 195 | 2011 |